Business Context and Reporting Period
This Form 8-K Current Report from Protagonist Therapeutics, Inc. (PTGX) covers the event date of January 1, 2023. The company is a Delaware corporation listed on The Nasdaq Stock Market LLC and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel change and does not contain financial statements or performance data.
Material Changes
Effective January 1, 2023, David Liu, the company's Chief R&D Strategy Officer, transitioned to a part-time R&D Strategy Advisor role due to health reasons. Consequently, Dr. Liu is no longer considered a Section 16 officer or an executive officer of the company.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, contingencies, or unusual items beyond the disclosed personnel transition.
Investor Verification Checklist
- Confirm the effective date of Dr. Liu's transition to a non-executive advisory role.
- Verify if the company has appointed a replacement for the Chief R&D Strategy Officer position.
- Review subsequent filings for any impact of this personnel change on the company's R&D pipeline or strategic direction.